Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
LifeMDLFMD -2.03%73 3-Year EBITDA Growth Rate is 69.20% as of Jun. 2026. GuruFocus rates LFMD with a GF Score™ of 73/100 and a GF Value™ of $5.09 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 526 Healthcare Providers & Services companies, LifeMD ranks better than 96.01% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 69.20% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 58.40% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was -13.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of LifeMD was 69.20% per year. The lowest was -202.70% per year. And the median was -28.70% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
LifeMD 3-Year EBITDA Growth Rate Related Terms
LFMD vs AMWL, SY, HCAT: 3-Year EBITDA Growth Rate Comparison
For the Health Information Services subindustry, LifeMD's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
LifeMD 3-Year EBITDA Growth Rate vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, LifeMD's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where LifeMD's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 69.20% mean?
LifeMD (LFMD) has a 3-Year EBITDA Growth Rate of 69.20% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for LifeMD and its competitors. According to the industry distribution chart, LifeMD ranks #21 out of 526 companies in the Healthcare Providers & Services industry, placing it in the top 4%.
Is LifeMD's 3-Year EBITDA Growth Rate too high?
LifeMD's current 3-Year EBITDA Growth Rate is 69.20%. The Healthcare Providers & Services industry median 3-Year EBITDA Growth Rate is 10.20. LifeMD's value of 69.20% is 578.4% above this industry median. Based on the distribution chart, LifeMD ranks #21 out of 526 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, LifeMD has a GF Score™ of 73/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does LifeMD's 3-Year EBITDA Growth Rate compare to AMWL and SY?
According to the Healthcare Providers & Services industry distribution chart, LifeMD ranks #21 out of 526 companies for 3-Year EBITDA Growth Rate. This places LifeMD in the top 4% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 10.20. LifeMD's value of 69.20% is 578.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Healthcare Providers & Services company?
The median 3-Year EBITDA Growth Rate among Healthcare Providers & Services companies is 10.20, based on 526 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. LifeMD's current 3-Year EBITDA Growth Rate of 69.20% is 578.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for LifeMD and its competitors. For the Healthcare Providers & Services industry, the median 3-Year EBITDA Growth Rate is 10.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. LifeMD's current 3-Year EBITDA Growth Rate is 69.20%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LifeMD stock overvalued right now?
Based on GuruFocus' analysis, LifeMD (LFMD) is currently considered Possible Value Trap. The stock's GF Value™ is $5.09, compared to a current price of $3.39 — trading 33.5% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 69.20% and 578.4% above the Healthcare Providers & Services industry median of 10.20. LifeMD's overall GF Score™ is 73/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For LifeMD (LFMD), the current 3-Year EBITDA Growth Rate is 69.20% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is LifeMD (LFMD) Overvalued in 2026?
Based on GuruFocus' analysis, LifeMD stock appears to be undervalued.
The current stock price of $3.39 is trading 33.5% below its estimated GF Value™ of $5.09.
GuruFocus considers LifeMD to be Possible Value Trap.
Key valuation signals for LFMD:
3-Year EBITDA Growth Rate: 69.20%
GF Value™: $5.09 vs. price of $3.39 (33.5% below fair value)
Industry Position: 578.4% above the Healthcare Providers & Services median (#21 of 526)
No single metric tells the full story. See the LFMD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
LifeMD Inc is a patient-centric, direct-to-patient healthcare company providing a high-quality, cost-effective, and convenient way for patients to access virtual medical care and pharmacy services. The Company's portfolio of brands within continuing operations is now managed as a single operating segment, Telehealth. Telehealth platform integrates core capabilities, includes: A nationwide pharmacy network, A wholly-owned commercial pharmacy, A fully integrated patient care center, A direct-to-patient marketing infrastructure for acquisition and retention, and AI-enabled clinical and operational technologies.
73GF Score
Get the complete analysis for LFMD
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LFMD has been successfully added to your 
